Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-22-018801
Filing Date
2022-05-19
Accepted
2022-05-19 16:18:57
Documents
1
Period of Report
2022-05-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4127
  Complete submission text file 0000899243-22-018801.txt   5543
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Issuer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE, 2 CHURCH STREET HAMILTON D0 HM11
Business Address
Beetham Thomas W. (Reporting) CIK: 0001741382 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38541 | Film No.: 22943078